The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical outcome of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel as first line chemotherapy in metastatic pancreatic cancer.
 
Kazuo Watanabe
No Relationships to Disclose
 
Yusuke Hashimoto
Research Funding - Taiho Pharmaceutical (Inst)
 
Kumiko Umemoto
No Relationships to Disclose
 
Hideaki Takahashi
No Relationships to Disclose
 
Mitsuhito Sasaki
No Relationships to Disclose
 
Hiroshi Imaoka
Honoraria - Taiho Pharmaceutical
 
Izumi Ohno
No Relationships to Disclose
 
Shuichi Mitsunaga
Research Funding - ASLAN Pharmaceuticals (Inst); Bayer Yakuhin (Inst); Chugai Pharma (Inst); Merck Serono (Inst)
 
Masafumi Ikeda
Honoraria - Abbott Japan; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Kowa; Lilly Japan; Nippon Kayaku; Novartis Pharmaceuticals UK Ltd.; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Pharmaceutical
Consulting or Advisory Role - Bayer Yakuhin; Bristol-Myers Squibb; Lilly Japan; NanoCarrier
Research Funding - AstraZeneca (Inst); Baxter (Inst); Bayer Yakuhin (Inst); Boehringer Ingelheim (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); NanoCarrier (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Yakult Pharmaceutical (Inst); Zeria Pharmaceutical (Inst)